BMEA: Biomea Fusion, Inc. Company Short-Term Debt

Symbol and logo of brand Biomea Fusion, Inc. (BMEA)

The price action of Biomea Fusion, Inc. (BMEA) demonstrates metrics at the level of 0.00, while the business relies on the development of treatments for obesity and diabetes. Management is focusing on innovative beta-cell modulation for the therapy of oncology and endocrine disorders. Simultaneously, Biomea Fusion, Inc. (BMEA) is actively recruiting rare biochemists, stimulating expert loyalty through a system of options and grants.

BMEA (Biomea Fusion Inc) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

BMEA (Biomea Fusion Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Biomea Fusion|BMEA - Fair Value Consensus
- market capitalization information:
Market Value Biomea Fusion, Inc.|BMEA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Biomea Fusion|BMEA - Book Capitalization|Market Cap to Net Assets Ratio biomeafusion.com|BMEA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Biomea Fusion, Inc.|BMEA - Company Cumulative Debt|Debt to Book Value Biomea Fusion, Inc.|BMEA - Amount of Long-Term Liabilities|Company Short-Term Debts Biomea Fusion|Quick Ratio biomeafusion.com
- net income and valuation multiples indicators:
BMEA - Company Net Income
Basic company analysis:Biomea Fusion - BMEA
Mass-produced product of Biomea Fusion Corp

Biomea Fusion, Inc. (BMEA) integrates artificial intelligence and automation to develop diabetes medications, requiring significant expenditures on clinical trials. This indicator aggregates all creditor obligations maturing within one year. By analyzing financial liabilities with a term of up to 12 months, one can assess current liquidity and the debt load. This chart reflects the balance between borrowed capital and scaling rates. Investors need to see moderate activity here to ensure operational growth.

Who Biomea Fusion, Inc. competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|Matinas BioPharma Holdings, Inc. - Company Short-Term Debt|Spruce Biosciences - Company Short-Term Debts|Short-Term Debt Volume Galecto Inc GLTO|Carmell Corp (CTCX) - Company Short-Term Debt|Short-Term Debt Lumos Therapeutics (LUMO)|Company Short-Term Debt Organovo Holdings, Inc.|Company Current Liabilities radiuspharm.com (RDUS)